Engage Therapeutics' innovative inhalation therapy reaches the clinical end of Phase 2b

13, Engage Therapeutics announced that its oral inhalation therapy, Staccato alprazolam, reached the end of its main study in stage 2b clinical trial StATES for patients with epilepsy, stopping epilepsy within two minutes of treatment and significantly increasing the proportion of patients who did not relapse within two hours compared to the placebo group. In addition, the trial showed that Staccato alprazolam worked quickly, ending a patient's seizures in an average of just 30 seconds.Seizures can lead to uncontrollable limb movements, abnormal thinking and behavior, and abnormal perception. Physical movement can be intense and can lead to loss of consciousness. Epilepsy occurs when a group of nerve cells in the brain are activated uncontrolled, and eclampsia refers to seizures that originate in a limited part of the brain. There are currently two approved nasal spray therapies on the market, but they take at least 15 minutes to take effect, meaning they are too late to stop seizures that have already started.Staccato alprazolam is a small hand-held oral inhalation epileptic first aid therapy that combines FDA-approved Staccato delivery technology with the marketed drug alprazolam. With just one inhalation, it's easy to deliver apus. The Staccato system can quickly evaporate aption, allowing it to form aerosols, particles that can be used for deep lung transport to produce rapid systemic action. This may provide an effective way for people with epilepsy and their caregivers to prevent active seizures.The StATES trial, a randomized, double-blind Phase 2b clinical study involving 116 patients, was designed to assess the safety, effectiveness and availability of Staccato alprazolam in treating adult patients with ectopic or systemic seizures. The results of the trial showed that 50 out of 76 patients reached the primary endpoint, i.e. the patient stopped epilepsy within two minutes of treatment and did not relapse within two hours.“ I think epilepsy drugs need to be effective quickly and stop the condition in time for seizures," said Gregory T. Mayes, founder and CEO of Engage Therapeutics. As clinical trials progress, we hope to see Staccato alprazolam as soon as possible as an important tool for patients with epilepsy to alleviate the disease. " (
medicine Mingkangde
)